
Please try another search
On the 17th of February, Orbimed Advisors bought 1.3 million Corvus Pharmaceuticals Inc (NASDAQ:CRVS) shares for $4.5 million at an average price of $3.50 per share. Shares of Corvus Pharmaceuticals Inc are down -20.00% since the transaction.
Orbimed Advisors's holding in Corvus Pharmaceuticals Inc increased to about 8.1 million shares with the purchase.
Orbimed Advisors first bought Corvus Pharmaceuticals Inc stock in the first quarter of 2016. Orbimed Advisors also owns Bristol-Myers Squibb Co (NYSE:BMY), Merck (MRK), Larimar Therapeutics, Inc. (LRMR) and Pfizer (NYSE:PFE). Corvus Pharmaceuticals Inc is its number thirty five position by number of shares and market value among biotechnology & life sciences stocks.
In contrast, Millennium Management reduced CRVS shares.
By Gigi Zamora and Rajesh Kumar Singh NEW YORK (Reuters) - U.S. travelers braving the skies faced fewer flight delays and cancellations over the Fourth of July weekend when...
By Liz Moyer Investing.com -- Stocks of firms that benefit from economic growth were weighed down on Tuesday by new concerns about a recession ahead. Big lenders such as JPMorgan...
LOS ANGELES (Reuters) - The latest season of Netflix Inc (NASDAQ:NFLX)'s "Stranger Things" has pushed total viewership for the series to more than 1.15 billion hours, the...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.